Due to its good tolerability, antitumor properties, good PSA response rates and lower side effects than chemotherapy and hormone therapy, PSMA-RLT could also be a promising treatment option for patients with PCa with a low tumor burden and who have not yet reached the castration-resistant stage. The gene discussed is FOLH1; the disease is neoplasm.